Scott T. Tagawa, MD, MS

Articles

Antibody-Drug Conjugates Carve Out Space in Urothelial Carcinoma Landscape

November 12th 2020

Monoclonal antibodies have played a key role in the development of personalized oncology and have proven antitumor activity through multiple mechanisms, including direct transmembrane signaling leading to apoptosis, complement mediated cytotoxicity, antibody-dependent cellular cytotoxicity, and inhibiting tumor vasculature and stroma.

Dr. Tagawa on Ongoing Research With 225Ac-J591 in mCRPC

April 17th 2020

Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine and urology at Weill Cornell Medicine, and associate attending physician, Weill Cornell Medical Center/NewYork-Presbyterian Hospital, discusses ongoing research with 225Ac-J591 in metastatic castration-resistant prostate cancer.

Dr. Tagawa on Targeting PSMA in Prostate Cancer

April 10th 2020

Scott T. Tagawa, MD, MS, discusses the utility of beta and alpha emitters in targeting PSMA in prostate cancer.

Dr. Tagawa on Remaining Questions With PSMA-Targeted Radionuclide Therapy in mCRPC

March 28th 2020

Scott T. Tagawa, MD, MS, discusses remaining questions regarding treatment selection and PSMA imaging in metastatic castration-resistant prostate cancer.

Dr. Tagawa on Safety Profile of 225Ac-J591 in mCRPC

March 27th 2020

Scott T. Tagawa, MD, MS, discusses the safety profile of novel monoclonal antibody 225Ac-J591 in metastatic castration-resistant prostate cancer.

Dr. Tagawa on Preliminary Data With 225Ac-J591 in mCRPC

February 25th 2020

Scott T. Tagawa, MD, MS, discusses preliminary data with 225Ac-J591 in metastatic castration-resistant prostate cancer.

Dr. Tagawa Discusses the Development of Immunotherapy in Urothelial Cancer

April 14th 2017

Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the development of immunotherapy for patients with urothelial cancer.

x